Morgan Stanley analyst Matthew Harrison downgraded Biohaven Pharmaceutical to Equal Weight from Overweight, citing his view that the stock’s current valuation reflects a balanced risk/reward. However, he noted that he continues to see a high probability of success for lead product candidate rimegepant in the acute treatment of migraine and expects approval of the drug in early 2020. Harrison has a $55 price target on Biohaven shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.